Search Results - "LIPATOV, Oleg N" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Palbociclib and Letrozole in Advanced Breast Cancer

Palbociclib and Letrozole in Advanced Breast Cancer

by Finn, Richard S, Martin, Miguel, Rugo, Hope S, Jones, Stephen, Im, Seock-Ah, Gelmon, Karen, Harbeck, Nadia, Lipatov, Oleg N, Walshe, Janice M, Moulder, Stacy, Gauthier, Eric, Lu, Dongrui R, Randolph, Sophia, Diéras, Véronique, Slamon, Dennis J
Published in The New England journal of medicine (17.11.2016)

Get full text

Journal Article

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

by Hutson, Thomas E, Prof, Lesovoy, Vladimir, Prof, Al-Shukri, Salman, Prof, Stus, Viktor P, Prof, Lipatov, Oleg N, Prof, Bair, Angel H, PhD, Rosbrook, Brad, MS, Chen, Connie, PharmD, Kim, Sinil, MD, Vogelzang, Nicholas J, Prof
Published in The lancet oncology (01.12.2013)

Get full text

Journal Article

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

by ROBERT, Nicholas J, DIERAS, Véronique, PHAN, See-Chun, O'SHAUGHNESSY, Joyce, GLASPY, John, BRUFSKY, Adam M, BONDARENKO, Igor, LIPATOV, Oleg N, PEREZ, Edith A, YARDLEY, Denise A, CHAN, Stephen Y. T, XIAN ZHOU
Published in Journal of clinical oncology (01.04.2011)

Get full text

Journal Article

Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma

Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma

by NOSOV, Dmitry A, ESTEVES, Brooke, LIPATOV, Oleg N, LYULKO, Alexei A, ANISCHENKO, A. A, CHACKO, Raju T, DOVAL, Dinesh C, STRAHS, Andrew, SLICHENMYER, William J, BHARGAVA, Pankaj
Published in Journal of clinical oncology (10.05.2012)

Get full text

Journal Article

Axitinib versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial

Axitinib versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial

by Hutson, Thomas E, Al-Shukri, Salman, Stus, Viktor P, Lipatov, Oleg N, Shparyk, Yaroslav, Bair, Angel H, Rosbrook, Brad, Andrews, Glen I, Vogelzang, Nicholas J
Published in Clinical genitourinary cancer (01.02.2017)

Get full text

Journal Article

Phase II Study of Picoplatin As Second-Line Therapy for Patients With Small-Cell Lung Cancer

Phase II Study of Picoplatin As Second-Line Therapy for Patients With Small-Cell Lung Cancer

by Eckardt, John R, Bentsion, Dimitri L, Lipatov, Oleg N, Polyakov, Igor S, Mackintosh, Frederick R, Karlin, David A, Baker, Gizelle S, Breitz, Hazel B
Published in Journal of clinical oncology (20.04.2009)

Get full text

Journal Article

Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer

Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer

by Slamon, Dennis J, Diéras, Véronique, Rugo, Hope S, Harbeck, Nadia, Im, Seock-Ah, Gelmon, Karen A, Lipatov, Oleg N, Walshe, Janice M, Martin, Miguel, Chavez-MacGregor, Mariana, Bananis, Eustratios, Gauthier, Eric, Lu, Dongrui R, Kim, Sindy, Finn, Richard S
Published in Journal of clinical oncology (20.03.2024)

Get full text

Journal Article

RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE)

RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE)

by Wilke, Hansjochen, Van Cutsem, Eric, Oh, Sang Cheul, Bodoky, Gyorgy, Shimada, Yasuhiro, Hironaka, Shuichi, Sugimoto, Naotoshi, Lipatov, Oleg N., Kim, Tae-You, Cunningham, David, Ohtsu, Atsushi, Rougier, Philippe, Emig, Michael, Carlesi, Roberto, Chandrawansa, Kumari, Muro, Kei
Published in Journal of clinical oncology (20.01.2014)

Get full text

Journal Article

Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902)

Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902)

by Hutson, Thomas, Nosov, Dimitry, Tomczak, Piotr, Bondarenko, Igor, Lipatov, Oleg N., Sternberg, Cora N., Needle, Michael N., Eisen, Tim
Published in Journal of clinical oncology (20.05.2015)

Get full text

Journal Article

Characterizing tumor responses from RAINBOW, a randomized phase III trial of ramucirumab (RAM) plus paclitaxel (PAC) vs placebo (PBO) plus PAC in patients (pts) with previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma

Characterizing tumor responses from RAINBOW, a randomized phase III trial of ramucirumab (RAM) plus paclitaxel (PAC) vs placebo (PBO) plus PAC in patients (pts) with previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma

by Bodoky, Gyorgy, Gil-Delgado, Marian, Cascinu, Stefano, Lipatov, Oleg N., Cunningham, David, Van Cutsem, Eric, Muro, Kei, Chandrawansa, Kumari, Liepa, Astra M., Carlesi, Roberto, Ohtsu, Atsushi, Wilke, Hansjochen
Published in Journal of clinical oncology (01.02.2016)

Get full text

Journal Article

Experience with olaparib in the treatment of BRCA-associated tumors in real clinical practice. Observational study

Experience with olaparib in the treatment of BRCA-associated tumors in real clinical practice. Observational study

by Sultanbaev, Alexander V., Menshikov, Konstantin V., Musin, Shamil I., Nasretdinov, Ainur F., Fatikhova, Alfiya A., Izmailov, Adel A., Lipatov, Oleg N., Ayupov, Rustam T., Sultanbaeva, Nadezda I., Menshikova, Irina A., Serebrennikov, Grigorii A.
Published in Sovremennaia onkologiia : zhurnal kafedry onkologii RMAPO dlia nepreryvnogo poslediplomnogo obrazovaniia (15.07.2022)

Get full text

Journal Article

PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC)

PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC)

by Finn, Richard S., Martin, Miguel, Rugo, Hope S., Jones, Stephen E., Im, Seock-Ah, Gelmon, Karen A., Harbeck, Nadia, Lipatov, Oleg N., Walshe, Janice Maria, Moulder, Stacy L., Gauthier, Eric Roland, Lu, Dongrui (Ray), Randolph, Sophia, Diéras, Véronique, Slamon, Dennis J.
Published in Journal of clinical oncology (20.05.2016)

Get full text

Journal Article

Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial

Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial

by Mackey, John Robert, Lipatov, Oleg N., Martin, Miguel, Webster, Marc, Hegg, Roberto, Verma, Sunil, Ramos Vazquez, Manuel, Fresco, Rodrigo, Thireau, Francois, Houé, Vincent, Press, Michael F., Narasimhan, Ashok, Damaraju, Sambasivarao
Published in Journal of clinical oncology (20.05.2015)

Get full text

Journal Article

RAINBOW: A global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy—An age-group analysis

RAINBOW: A global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy—An age-group analysis

by Muro, Kei, Bodoky, Gyorgy, Cesas, Alvydas, Chao, Yee, Clingan, Philip, Hironaka, Shuichi, Komatsu, Yoshito, Kurteva, Galina Petrova, Lipatov, Oleg N., Nishina, Tomohiro, Oh, Sang Cheul, Ohtsu, Atsushi, Shimada, Yasuhiro, Sugimoto, Naotoshi, Van Cutsem, Eric, Carlesi, Roberto, Chandrawansa, Kumari, Wilke, Hansjochen
Published in Journal of clinical oncology (20.01.2015)

Get full text

Journal Article

RAINBOW: A global, phase 3, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy: Results of a multiple Cox regression analysis adjusting for prognostic factors

RAINBOW: A global, phase 3, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy: Results of a multiple Cox regression analysis adjusting for prognostic factors

by Wilke, Hansjochen, Van Cutsem, Eric, Oh, Sang Cheul, Bodoky, Gyorgy, Shimada, Yasuhiro, Hironaka, Shuichi, Sugimoto, Naotoshi, Lipatov, Oleg N., Kim, Tae-You, Cunningham, David, Rougier, Philippe, Emig, Michael, Carlesi, Roberto, Chandrawansa, Kumari, Muro, Kei, Ohtsu, Atsushi
Published in Journal of clinical oncology (20.05.2014)

Get full text

Journal Article

RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma: Quality-of-life (QoL) results

RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma: Quality-of-life (QoL) results

by Al-Batran, Salah-Eddin, Van Cutsem, Eric, Oh, Sang Cheul, Bodoky, Gyorgy, Shimada, Yasuhiro, Hironaka, Shuichi, Sugimoto, Naotoshi, Lipatov, Oleg N., Kim, Tae-You, Cunningham, David, Rougier, Philippe, Muro, Kei, Liepa, Astra M., Ballal, Shaila, Emig, Michael, Ohtsu, Atsushi, Wilke, Hansjochen
Published in Journal of clinical oncology (20.05.2014)

Get full text

Journal Article

Subgroup analyses of a phase III trial comparing tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)

Subgroup analyses of a phase III trial comparing tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)

by Hutson, Thomas E., Nosov, Dmitry, Eisen, Timothy, Lipatov, Oleg N., Tomczak, Piotr, Alyasova, Anna, Harza, Mihai, Kogan, Mikhail, Alexseev, Boris Y., Szczylik, Cezary, Strahs, Andrew Louis, Esteves, Brooke, Berkenblit, Anna, Motzer, Robert John
Published in Journal of clinical oncology (20.02.2013)

Get full text

Journal Article

Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial

Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial

by Motzer, Robert John, Nosov, Dmitry, Eisen, Tim, Bondarenko, Igor N., Lesovoy, Vladmir, Lipatov, Oleg N., Tomczak, Piotr, Lyulko, Alexey A., Alyasova, Anna, Harza, Mihai, Kogan, Mikhail, Alexeev, Boris Y., Sternberg, Cora N., Szczylik, Cezary, Zhang, Joshua, Strahs, Andrew Louis, Esteves, Brooke, Slichenmyer, William J., Berkenblit, Anna, Hutson, Thomas E.
Published in Journal of clinical oncology (20.05.2012)

Get full text

Journal Article

$Safety and Tolerability of the Combination of Interleukin-2 (rIL-2) and Rituximab in Patients with Refractory/Relapsed Follicular Non Hodgkin Lymphoma. Preliminary Data from the Pearl Study$

Safety and Tolerability of the Combination of Interleukin-2 (rIL-2) and Rituximab in Patients with Refractory/Relapsed Follicular Non Hodgkin Lymphoma. Preliminary Data from the Pearl Study

by Diaz, Nieves, Osmanov, Eugeny A., Alexeeva, Yulia A., Byakhov, Mikhail Yu, Lipatov, Oleg N., Kravchenko, Sergey K., Zuzgin, Ilya S., Garzon, Felix T., Elias, Laurence, Solal-Celigny, Philippe
Published in Blood (16.11.2005)

Get full text

Journal Article

Phase II Study of Picoplatin As Second-Line Therapy for Patients With Small-Cell Lung Cancer

Phase II Study of Picoplatin As Second-Line Therapy for Patients With Small-Cell Lung Cancer

by ECKARDT, John R, BENTSION, Dimitri L, LIPATOV, Oleg N, POLYAKOV, Igor S, MACKINTOSH, Frederick R, KARLIN, David A, BAKER, Gizelle S, BREITZ, Hazel B
Published in Journal of clinical oncology (2009)

Get full text

Journal Article